Healthcare & Medical Devices Global On demand · 24-48h

Global Cardiovascular Prosthetic Products Market Strategic Research Report

Global Cardiovascular Prosthetic Products Market Strategic R…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Cardiovascular Prosthetic Products Market
$31.08B2025
8.9%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Cardiac Prosthetic Products, Vascular Prosthetic Products

By Application: Hospitals, Clinics, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Abbott Laboratories, B Braun Melsungen AG, Boston Scientific Corporation, Biotronic, W. L. Gore & Associates, Inc, Artivion, Inc, Johnson and Johnson, Medtronic Plc, Meril Life Sciences Pvt. Ltd, Edwards Lifesciences, Terumo Group, Maquet Cardiovascular, Gore, Nicast, Bard, Jude Medical, LeMaitre Vascular, Lifetech Scientific, BiVACOR, SynCardia, Jarvik Heart, Inc, CARMAT, AbioMed

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 151 pages
Market size 2025
$31.08B
Billion USD
Forecast CAGR
8.9%
2025-2032
Forecast 2032
$56.5B
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

نظرة عامة

Scope of the Report

The global Cardiovascular Prosthetic Products market size is predicted to grow from US$ 31,080 million in 2025 to US$ 55,810 million in 2032; it is expected to grow at a CAGR of 8.9% from 2026 to 2032.

Cardiovascular Prosthetic Products are implantable or external devices that replace or assist parts of the cardiovascular system, such as the heart, arteries, or veins. Examples of cardiovascular prosthetic devices include pacemakers, implanted heart valves, artificial vascular grafts, and stents. These devices significantly improve quality of life and are normally installed by a heart surgeon. They are also used to treat a number of cardiac conditions, including valvular heart disease, congenital heart defects, arrhythmias, coronary artery disease, and heart failure. Aortic aneurysm repair, valve replacement, endovascular stenting, ventricular assist devices, transcatheter aortic valve replacement (TAVR), and other procedures all involve these cardiovascular prosthetic devices.

According to report shared by Center for Disease Control and Prevention (CDC), in 2020, it was stated that, coronary heart disease is the most common type of heart disease, killing 382,820 people in U.S. Moreover, in 2020, about 2 in 10 deaths from coronary artery disease (CAD) happen in adults less than 65 years old. Increase in number of cardiovascular surgeries is anticipated to drive the application of cardiovascular prosthetic devices and boosts market growth. For instance, according to National Library of Medicine in September 2022, it was reported that, more than 200,000 heart valve replacement surgeries are performed annually worldwide, with a predicted increment to 8,50,000 per year by 2050. In addition, according to National Library of Medicine in August 2022, almost 400,000 coronary artery bypass grafting (CABG) surgeries are performed each year making it the most-performed major surgical procedure.

This report presents a comprehensive overview of the global Cardiovascular Prosthetic Products market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Cardiac Prosthetic Products
  • Vascular Prosthetic Products

Segment by Application

  • Hospitals
  • Clinics
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Cardiovascular Prosthetic Products market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospitals, Clinics, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Cardiovascular Prosthetic Products Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 8.9%
Regional growth momentum
Market share by segment
Key metrics
Base value
$31.08B
2025
Forecast
$56.5B
2032
CAGR
8.9%
2025–2032
Regions
5
global
Key companies
Abbott LaboratoriesB Braun Melsungen AGBoston Scientific CorporationBiotronicW. L. Gore & Associates, IncArtivion, IncJohnson and JohnsonMedtronic Plc
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Cardiac Prosthetic ProductsVascular Prosthetic Products
By Application
HospitalsClinicsOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Cardiac Prosthetic Products
  • 3.1.3 Vascular Prosthetic Products
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospitals
  • 4.1.3 Clinics
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Abbott Laboratories
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 B Braun Melsungen AG
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Boston Scientific Corporation
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Biotronic
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 W. L. Gore & Associates, Inc
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Artivion, Inc
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Johnson and Johnson
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Medtronic Plc
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Meril Life Sciences Pvt. Ltd
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Edwards Lifesciences
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Terumo Group
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Maquet Cardiovascular
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Gore
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Nicast
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Bard
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Jude Medical
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 LeMaitre Vascular
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Lifetech Scientific
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 BiVACOR
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 SynCardia
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Jarvik Heart, Inc
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 CARMAT
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 AbioMed
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Cardiovascular Prosthetic Products market?
The global Cardiovascular Prosthetic Products market is estimated at US$ 31.08 billion in 2025 (base year) and is projected to reach US$ 55.81 billion by 2032.
How fast is the Cardiovascular Prosthetic Products market expected to grow?
The market is expected to grow at a CAGR of 8.9% from 2026 to 2032, expanding from US$ 31.08 billion in 2025 to US$ 55.81 billion in 2032, roughly 1.8 times its base-year value.
What does the Cardiovascular Prosthetic Products market cover?
Cardiovascular Prosthetic Products are implantable or external devices that replace or assist parts of the cardiovascular system, such as the heart, arteries, or veins. Examples of cardiovascular prosthetic devices include pacemakers, implanted heart valves, artificial vascular grafts, and stents. These devices significantly improve quality of life and are normally installed by a heart surgeon.
What are the main segments of the Cardiovascular Prosthetic Products market by type?
By type, the market is segmented into Cardiac Prosthetic Products and Vascular Prosthetic Products.
Which applications drive demand in the Cardiovascular Prosthetic Products market?
Key applications covered include Hospitals, Clinics and Others.
Who are the key players in the Cardiovascular Prosthetic Products market?
Key players profiled include Abbott Laboratories, B Braun Melsungen AG, Boston Scientific Corporation, Biotronic, W. L. Gore & Associates, Artivion, Johnson and Johnson and Medtronic Plc, among 23 companies covered in total.
Which regions and countries are covered for Cardiovascular Prosthetic Products?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Cardiovascular Prosthetic Products market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospitals, Clinics and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Cardiovascular Prosthetic Products market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from ‏3,500.00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.